Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 2,447 matching trials from the live ClinicalTrials.gov search.
Conditions
Peripheral Artery Disease
Interventions
Lutonix Drug Coated Balloon
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
39
States / cities
Los Angeles, California • Oceanside, California • Orange, California + 32 more
Conditions
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
Interventions
Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Columbus, Georgia • Kingwood, Texas • Blacksburg, Virginia
Conditions
Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions
Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
Drug · Biological · Radiation + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Adenocarcinoma Pancreas
Interventions
Surgery, Genetic Expression, Chemotherapy
Procedure · Genetic · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Selected Advanced Solid Tumors
Interventions
MEDI5752, Pemetrexed, Carboplatin, Pembrolizumab, Paclitaxel or Nab-Paclitaxel
Biological · Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Detroit, Michigan • New York, New York • Chapel Hill, North Carolina + 4 more
Conditions
Sarcoma
Interventions
paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Up to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 52 more
Conditions
Neoplasm
Interventions
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU), Paclitaxel for injection (Taxol)
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Breast Cancer
Interventions
5-Fluorouracil, Cyclophosphamide, Doxorubicin, Paclitaxel, Epirubicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
Cetuximab, Paclitaxel, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
14
States / cities
Little Rock, Arkansas • Long Beach, California • Boynton Beach, Florida + 11 more
Conditions
HER2 Positive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Paclitaxel, Trastuzumab
Drug · Other · Biological
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Norfolk, Nebraska • Omaha, Nebraska
Conditions
Esophageal Carcinoma
Interventions
Tetrathiomolybdate (TM), Radiation, Surgery
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 2 Interventional Results available

Trial of NanoPac Intratumoral Injection in Lung Cancer

NCT04314895
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer, Lung Cancer, Small Cell, Neoplasm of Lung
Interventions
NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Drug
Lead sponsor
NanOlogy, LLC
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Gainesville, Florida • Fort Wayne, Indiana • Baltimore, Maryland + 1 more
Conditions
Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Interventions
Nivolumab, (8gy x 3), Platinum Doublet
Drug · Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
4
States / cities
St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more
Conditions
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreas Metastases, Adenocarcinoma
Interventions
Paricalcitol (Zemplar)
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Endometrial Cancer
Interventions
Carboplatin/Paclitaxel, Trastuzumab
Drug
Lead sponsor
Yale University
Other
Eligibility
Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 16 more
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Interventions
Carboplatin, Cisplatin, External Beam Radiation Therapy, Internal Radiation Therapy, Paclitaxel
Drug · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
14
States / cities
Orange, California • Hartford, Connecticut • New Britain, Connecticut + 9 more
Conditions
Lung Cancer
Interventions
carboplatin, chemotherapy, efaproxiral, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
10
States / cities
Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 6 more
Conditions
Head and Neck Cancer
Interventions
Abraxane, Cetuximab
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Orange, California
Conditions
Ovarian Cancer
Interventions
Paclitaxel, Bevacizumab, Lurbinectedin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Triple Negative Breast Neoplasms
Interventions
Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Columbia, Maryland • Boston, Massachusetts + 4 more
Conditions
HPV, Throat Cancer, Oropharyngeal Carcinoma, Oropharyngeal Cancer, Human Papilloma Virus
Interventions
18 F-FMISO PET/CT, Radiation, Cisplatin, Carboplatin, 5-fluorouracil
Diagnostic Test · Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Prostate Cancer
Interventions
DHA-paclitaxel
Drug
Lead sponsor
Theradex
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
8
States / cities
Tucson, Arizona • Berkeley, California • Lexington, Kentucky + 5 more
Conditions
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Squamous Cell Carcinoma of the Bladder, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions
trastuzumab, paclitaxel, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
ABI-007 (Abraxane), bevacizumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fresno, California + 32 more